Do Not Step Down to Ciprofloxacin if the Initial Susceptibility Test Showed Resistance
You should not step down to ciprofloxacin when the initial susceptibility testing demonstrated resistance, regardless of clinical improvement on ceftazidime-avibactam (Zerbaxa). This is a fundamental principle of antimicrobial stewardship and infectious disease management.
Core Principle: Susceptibility Testing Must Guide Therapy
The IDSA guidelines explicitly state that initial empirical therapy should be tailored appropriately on the basis of the infecting uropathogen 1. This principle applies equally—if not more critically—to de-escalation decisions. When susceptibility data show resistance, that organism will not be adequately treated by the resistant antibiotic, even if the patient appears clinically improved.
Why This Matters in Your Hemodialysis Patient
For your 85-year-old hemodialysis patient, several factors make stepping down to a resistant antibiotic particularly dangerous:
- Immunocompromised state: Hemodialysis patients have impaired immune function, making them more vulnerable to treatment failures
- Limited vascular access: Recurrent infections could jeopardize dialysis access 2, 3
- Higher mortality risk: Polymicrobial and resistant infections in hemodialysis patients carry significantly increased morbidity and mortality 3
- Drug accumulation risk: Ciprofloxacin requires dose adjustment in renal failure; inappropriate dosing could lead to toxicity without efficacy
The Evidence Against Using Resistant Antibiotics
The IDSA guidelines note that even in clinical trials, women with uropathogens resistant to the study drug who continued receiving that drug experienced clinical failure 1. In one study, 14 women in the trimethoprim-sulfamethoxazole group with resistant organisms continued therapy—this was a research protocol violation, not a recommended practice. The ciprofloxacin group had only 1 such case, highlighting that resistance predicts failure.
Appropriate De-escalation Strategy
The correct approach is to step down based on susceptibility results, not based on the spectrum of the initial antibiotic. The ESCMID guidelines specifically recommend this as good clinical practice: "stepdown targeted therapy following carbapenems once patients are stabilized, using old BLBLI, quinolones, cotrimoxazole or other antibiotics based on the susceptibility pattern of the isolate" 4.
For your patient, appropriate oral step-down options include:
- Trimethoprim-sulfamethoxazole if susceptible (160/800 mg twice daily for 14 days) 1
- Oral beta-lactams if susceptible (though less effective than other options) 1
- Other fluoroquinolones (e.g., levofloxacin) only if susceptibility testing shows sensitivity—do not assume cross-resistance patterns
Special Considerations for Hemodialysis
The Zerbaxa (ceftazidime-avibactam) label specifically addresses renal impairment: dosage adjustment is required in adult patients with CrCl ≤50 mL/min or less, including adult patients with ESRD on hemodialysis 5. If continuing parenteral therapy is necessary:
- Zerbaxa can be removed by hemodialysis (approximately 66% of ceftazidime and 56% of tazobactam removed) 5
- Dosing should be administered after dialysis 2
- Recent pharmacokinetic studies suggest dosing regimens of 1.875g every 24 hours with PIRRT scheduled appropriately 6
Common Pitfall to Avoid
Do not confuse clinical improvement with microbiological cure. A patient may appear better due to:
- Source control (catheter removal, abscess drainage)
- Immune response
- Suppression (not eradication) of bacterial load
Switching to a resistant antibiotic risks relapse, persistent bacteremia, or development of further resistance. In hemodialysis patients, this can lead to loss of vascular access, endocarditis, or metastatic infection 3.
The Bottom Line
Resistance on susceptibility testing is an absolute contraindication to using that antibiotic for step-down therapy. Choose an alternative oral agent to which the organism is susceptible, or continue appropriate parenteral therapy if no suitable oral options exist. This protects your patient from treatment failure and prevents the development of additional resistance.